2017 Press Releases

Webcast ImageWebcast
ChromaDex Year End 2016 Conference Call (Replay)
03/17/17 at 1:00 p.m. ET
ChromaDex Year End 2016 Conference Call
Friday, March 17, 2017 1:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
03/16/17ChromaDex Reports 2016 Record Revenue as Ingredient Sales Grew 34%
Q4 Total Revenue Increased 29% and 2016 Total Revenue Increased 22% IRVINE, Calif., March 16, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today the financial results for the year ended Dec. 31, 2016. “We finished 2016 on a strong note, generating 29% year over ... 
Printer Friendly Version
03/10/17ChromaDex to Report Year End 2016 Financial Results on Thursday, March 16, 2017
Company Will Host Investor Conference Call on Friday, March 17, 2017 IRVINE, Calif., March 10, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its year end 2016 financial results on Thursday, March 16, after the close of the financial... 
Printer Friendly Version
02/23/17A Letter from the ChromaDex Chief Executive Officer
IRVINE, Calif., Feb. 23, 2017 (GLOBE NEWSWIRE) -- The following is issued on behalf of ChromaDex: Dear Fellow Shareholders: In January 2016, I issued a shareholder letter wherein I described in some detail my enthusiasm surrounding the enormous commercial opportunity we have with our patented NIAGEN® nicotinamide riboside (NR), a next-generation form of Vitamin B3 with what I believe has blockbuster potential in the emerging category of NAD+ (nicotinamide adenine dinucleotide) precursors. ... 
Printer Friendly Version
02/22/17Study Published in PAIN Reveals Nicotinamide Riboside is an Effective Tool in Relieving Chemotherapy-Induced Peripheral Neuropathy Induced by a Common Anticancer Agent
Early findings demonstrated in female rats may one day lead to reductions in the neuropathic pain experienced by millions of breast and ovarian cancer patients and survivors IRVINE, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC) an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that Unive... 
Printer Friendly Version
02/21/17ChromaDex to Showcase Premier Innovation and Brand-Elevating Science at Engredea 2017
IRVINE, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today it is bringing some of its top industry-advancing health and wellness products and services to booth #868 at Engredea 2017, taking place March 9-12 in Anaheim, CA.  ChromaDex is confident ... 
Printer Friendly Version
02/14/17ChromaDex Expects to Report Record Fourth Quarter as Revenue Increased Approximately 29%
Q4 2016 Revenue is Expected to be Approximately $5.6 Million with Full-Year 2016 Revenue of Approximately $26.8 million IRVINE, Calif., Feb. 14, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today preliminary and unaudited revenue for the fourth quarter ended Decem... 
Printer Friendly Version
01/05/17ChromaDex Opens New State-of-the-Art Research and Development Center in Longmont
R&D Facility an Important Milestone for ChromaDex to Continue Global Leadership in the Identification and Development of NAD+ Metabolites IRVINE, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Today, ChromaDex Corporation (https://www.chromadex.com/)  (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, is announcing the of... 
Printer Friendly Version
01/04/17ChromaDex to Present at the ICR Conference 2017 on January 11, 2017
IRVINE, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that its Chief Executive Officer and Founder, Frank Jaksch, will present at the ICR Conference 2017. The conference will be held January 9-11, 2017, at the JW Marriott Orlando Grande Lakes ... 
Printer Friendly Version